SmartTRAK was cited as a source in a press release from Smith & Nephew entitled "Smith & Nephew expands opportunity in meniscal repair through acquisition of unique and highly complementary technology."
Cerapedics’ CEO Glen Kashuba and President and COO Jeff Marx, Ph.D. discuss the future of the bone graft substitutes and the uniqueness of i‑FACTOR Peptide Enhanced Bone Graft, a small peptide technology in an interview with Kim French, Sr. Analyst, SmartTRAK Orthbio.
A transcript of SmartTRAK's interview with Glen Kashuba and Jeff Marx is below, or click on the following video to listen to the interview.
Up 3.4% YoY, the OrthoBio market is off to a good start. Companies that are surpassing growth expectations tend to have differentiated products, focused efforts and incremental pull through from synergistic sales strategies. Market subtleties like reimbursement, pricing pressures and market loss due to newer competition continue to afflict some companies and segments...
Among the many topics covered in the full Q118 OrthoBio Market Recap are:
Hurricane related disruptions, competition and sales force dynamics impacts third quarter results
By Kim French, Senior Analyst, SmartTRAK OrthoBio
For Q317, the US OrthoBio Market grew substantially, compared to Q316. Both positive and negative developments are impacting company results. Positive happenings include increased revenue generation from synergistic sales strategies, market share capture and expansion of new users or new products. Companies experiencing lower than expected performance report hurricane related disruptions, slow ramp-up of sales force expansion, product portfolio gaps and market share loss due to increased competition.
SmartTRAK's President & CEO Sharon O'Reilly attended DKOU2017, the German Congress of Orthopedic and Trauma Surgery, in Berlin Oct. 24-27, 2017 and uncovered several new and innovative orthopedic, trauma and spine technologies on the exhibit floor.
This week, the SmartTRAK blog is featuring video interviews from DKOU highlighting new companies and products emerging from Europe.
Next up ...
Leanna Caron, EVP & CCO and Dr. James Howe, Founder & CMO - AgNovos Healthcare: A minimally invasive injectable technique for stabilizing osteoporotic hips
Vivorté, Inc., a vertically-integrated, specialty orthopedic biomaterials company, announced the commercial availability of a complete line of bone grafting product solutions.
Injectable treatments will never turn a bad joint into a good one but may relieve pain for an undetermined period of time, concludes Elizaveta Kon, MD, in a conversation with BioMedGPS at the 2016 ICRS. Dr. Kon has performed extensive research comparing injectable technologies (e.g., PRP, HA, BMAC) and believes their primary role is in treating pain in pts who wish to avoid surgery.
AAOS Shifts Focus From Efficacy to Cost
The American Association of Orthopedic Surgeons (AAOS) has shifted their focus from efficacy to costs in their offensive against intra-articular hyaluronic acid therapy